In today's world, 3-MeO-PCMo is a topic of constant interest and covers a wide range of aspects. From its influence on society to its implications on the global economy, 3-MeO-PCMo has become a focal point in everyday conversations. With an impact that transcends borders and cultures, 3-MeO-PCMo has positioned itself as a relevant and constantly evolving topic. In this article, we will explore different perspectives and approaches related to 3-MeO-PCMo, with the aim of understanding its importance in the current context and its projection for the future.
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C17H25NO2 |
| Molar mass | 275.392 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
3-MeO-PCMo is a dissociative anesthetic drug which is similar in structure to phencyclidine[1][2] and been sold online as a designer drug.[3][4] The inhibitory effect of 3-MeO-PCMo on the reduction in the density of the drebrin clusters by NMDAR stimulation with glutamic acid is lower than that of PCP or 3-MeO-PCP, with half maximal inhibitory concentration (IC50) values of 26.67 μM (3-MeO-PCMo), 2.02 μM (PCP) and 1.51 μM (3-MeO-PCP).[5]